Related Experiment Video
Updated: Feb 27, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
KIBRA attains oncogenic activity by repressing RASSF1A
Anuj1, Lakshmi Arivazhagan1, Rohan Prasad Surabhi1
1Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600036, India.
Background:
KIBRA-initially identified as a neuronal associated protein is now shown to be functionally associated with other tissue types as well. KIBRA interacts with dyenin light chain 1 and this interaction is essential for oestrogen receptor transactivation in breast cancer cells. KIBRA as a substrate of Cdk1, Aurora kinase and ERK plays an important role in regulating cell cycle, cell proliferation and migration. Despite these evidences, the exact role of KIBRA in cancer progression is not known.
Methods:
We studied the expression of KIBRA in breast tissues and breast cancer cell lines by western blotting, immunohistochemisry (IHC) and RT-PCR. Stable over expression and knockdown clones were generated to study the transforming properties of KIBRA by conventional assays. Xenograft studies were performed in nude mice to study the in vivo tumourigenic efficacy of KIBRA. qPCR array was performed to understand the molecular mechanism behind oncogenic activity of KIBRA.
Results:
Our results showed that KIBRA is upregulated in breast cancer cells and in malignant human breast tumours by both western blotting and IHC. Interestingly, we found that KIBRA expression level goes up with increase in breast cancer progression in well-established MCF10A model system. Further, results from stable overexpression clones of KIBRA in fibroblasts (Rat-1) and epithelial breast cancer cells (ZR75) and lentiviral short hairpin RNA-mediated knockdown (KD) clones of KIBRA in ZR75 showed increase in transforming properties with KIBRA overexpression and vice-versa. Results also showed that fibroblasts stably overexpressing KIBRA showed increased tumourigenic potential in nude mice. By adopting a quantitative PCR array-based approach, we identified RASSF1A, a tumour suppressor, as a transcriptional target of KIBRA.
Conclusions:
This is the first study to demonstrate the in vivo tumourigenic property of KIBRA in a nude mouse model and also unravel the underlying molecular mechanism of KIBRA-mediated transformation via repression of RASSF1A.British Journal of Cancer advance online publication, 29 June 2017; doi:10.1038/bjc.2017.192 www.bjcancer.com.
Insights
KIBRA protein is upregulated in breast cancer, promoting tumor growth and progression by repressing the tumor suppressor RASSF1A. This study demonstrates KIBRA's in vivo tumor-forming ability and its oncogenic mechanism.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- KIBRA, initially identified as a neuronal protein, is implicated in various cellular functions beyond the nervous system.
- KIBRA interacts with dynein light chain 1, crucial for estrogen receptor transactivation in breast cancer.
- KIBRA acts as a substrate for key kinases (Cdk1, Aurora, ERK), regulating cell cycle, proliferation, and migration.
Purpose of the Study:
- To investigate the role of KIBRA in breast cancer progression.
- To elucidate the molecular mechanisms underlying KIBRA's potential oncogenic activity.
Main Methods:
- KIBRA expression analyzed in breast tissues and cell lines using Western blotting, IHC, and RT-PCR.
- Stable KIBRA overexpression and knockdown cell lines generated to assess transforming properties.
- In vivo tumorigenic efficacy evaluated through xenograft studies in nude mice.
- Quantitative PCR array used to identify molecular targets of KIBRA.
Main Results:
- KIBRA is significantly upregulated in breast cancer cells and tumors, correlating with disease progression.
- Overexpression of KIBRA enhanced transforming properties in fibroblasts and breast cancer cells, while knockdown reduced them.
- Fibroblasts overexpressing KIBRA exhibited increased tumor-forming potential in vivo.
- RASSF1A, a known tumor suppressor, identified as a transcriptional target repressed by KIBRA.
Conclusions:
- This study provides the first evidence of KIBRA's in vivo tumorigenic capacity.
- KIBRA promotes cancer cell transformation by repressing the tumor suppressor RASSF1A.
- KIBRA represents a potential therapeutic target in breast cancer treatment.
More Related Videos
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...